Upstart cancer biotech recruits a top Pfizer oncology researcher as CSO — could an IPO be far behind?
As Vividion execs proudly showed off an $82 million B round last spring, the startup was eager to discuss 3 preclinical programs —an adaptor protein, a transcription factor and an E3 ligase — that were angling toward proof-of-concept data. Now they have found a high-profile early-stage pharma exec to guide them to the promised land of clinical development.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 72,800+ biopharma pros reading Endpoints daily — and it's free.